William E Delaney Selected Research

Antiviral Agents (Antivirals)

1/2022	Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
1/2018	Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
12/2014	Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir.
1/2014	Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
7/2013	Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome.
1/2013	Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures.
7/2006	Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
7/2005	Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
6/2004	Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William E Delaney Research Topics

Disease

18	Infections 01/2023 - 08/2002
18	Chronic Hepatitis B 01/2023 - 08/2002
3	Hepatitis B 07/2013 - 12/2003
2	Viremia 03/2020 - 07/2005
2	Persistent Infection 02/2012 - 06/2004
1	Disease Progression 11/2022
1	Genetic Translocation (Chromosomal Translocation) 01/2021
1	Hepatitis C 12/2014
1	Coinfection 05/2007
1	HIV Infections (HIV Infection) 07/2005
1	Body Weight (Weight, Body) 07/2005

Drug/Important Bio-Agent (IBA)

9	Antiviral Agents (Antivirals)IBA 01/2022 - 06/2004
7	adefovir dipivoxil (Hepsera)FDA Link 05/2007 - 08/2002
5	NucleotidesIBA 05/2013 - 01/2005
5	NucleosidesIBA 05/2013 - 07/2003
4	Lamivudine (Epivir)FDA Link 05/2007 - 11/2003
3	Circular DNAIBA 01/2023 - 12/2003
3	GS-9256IBA 01/2017 - 02/2012
3	adefovirIBA 05/2007 - 07/2003
2	AntigensIBA 01/2023 - 07/2005
2	Toll-Like Receptor 8IBA 01/2021 - 01/2020
2	selgantolimodIBA 01/2021 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2003
2	vesatolimodIBA 01/2018 - 01/2018
2	Toll-Like Receptor 7IBA 01/2018 - 01/2018
2	InterferonsIBA 01/2017 - 05/2013
2	GS-9451IBA 12/2014 - 01/2014
2	Protease Inhibitors (Protease Inhibitor)IBA 01/2014 - 07/2009
2	Hepatitis B e AntigensIBA 05/2007 - 01/2003
2	ProTidesIBA 05/2007 - 01/2007
2	Tenofovir (Viread)FDA Link 07/2006 - 07/2005
1	RNA (Ribonucleic Acid)IBA 01/2023
1	nasIBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 11/2022
1	histone H3 trimethyl Lys4IBA 01/2022
1	Peptides (Polypeptides)IBA 03/2020
1	Taurocholic Acid (Sodium Taurocholate)IBA 03/2020
1	hepatitis B virus X proteinIBA 01/2017
1	CytokinesIBA 01/2017
1	Peptide Hydrolases (Proteases)FDA Link 12/2014
1	phosphonic acidIBA 07/2009
1	Interferon-alpha (Interferon Alfa)IBA 05/2007
1	ProdrugsIBA 07/2006
1	Surface Antigens (Surface Antigen)IBA 07/2005
1	Codon (Codons)IBA 01/2003
1	Proteins (Proteins, Gene)FDA Link 01/2003

Therapy/Procedure

10	Therapeutics 03/2020 - 08/2002
1	Aftercare (After-Treatment) 05/2013
1	Liver Transplantation 05/2007
1	Oral Administration 07/2005